Comment from U.S. Pharmacopeia

Summary: The United States Pharmacopeia (USP) supports the draft guidance on using new approach methodologies (NAMs) in drug development, noting its alignment with human-centric, nonanimal testing and global scientific efforts. They advocate for a weight-of-evidence framework for evaluating novel excipients and emphasize the importance of integrating NAMs data to reduce animal testing.